Russia’s novel vaccine developed and produced by the Gameleya Research Institute in collaboration with the Russian Direct Investment Fund (RDIF) is made available to the public after the end of the first phase / second trials. However, scientists have conducted Phase III trials simultaneously, testing it at 40,000 people. The move came after the vaccine faced a lot of backlash from global authorities, who criticized the role as ‘insecure’.
While Russian authorities were quick to rule out problems related to security concerns, officials are now extensively testing the vaccine to make it attractive to the public.
Russia intends to enter into a strategic alliance with India for the production and scale-up of the vaccine under trial.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ